CN110627784B - 抗流感病毒嘧啶衍生物 - Google Patents

抗流感病毒嘧啶衍生物 Download PDF

Info

Publication number
CN110627784B
CN110627784B CN201910800685.0A CN201910800685A CN110627784B CN 110627784 B CN110627784 B CN 110627784B CN 201910800685 A CN201910800685 A CN 201910800685A CN 110627784 B CN110627784 B CN 110627784B
Authority
CN
China
Prior art keywords
acid
compound
pharmaceutically acceptable
acceptable salt
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910800685.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110627784A (zh
Inventor
熊剑
龙超峰
王晶晶
陈小新
陈新海
谢程
李鹏
彭宣嘉
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Raynovent Biotech Co Ltd
Original Assignee
Guangdong Raynovent Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Raynovent Biotech Co Ltd filed Critical Guangdong Raynovent Biotech Co Ltd
Publication of CN110627784A publication Critical patent/CN110627784A/zh
Application granted granted Critical
Publication of CN110627784B publication Critical patent/CN110627784B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201910800685.0A 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物 Active CN110627784B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610804101 2016-09-05
CN2016108041013 2016-09-05
CN201611238759 2016-12-28
CN2016112387599 2016-12-28
CN201780054195.XA CN109790159B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780054195.XA Division CN109790159B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Publications (2)

Publication Number Publication Date
CN110627784A CN110627784A (zh) 2019-12-31
CN110627784B true CN110627784B (zh) 2021-09-21

Family

ID=61300177

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910800685.0A Active CN110627784B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物
CN201780054195.XA Active CN109790159B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物
CN201910800902.6A Active CN110623958B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201780054195.XA Active CN109790159B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物
CN201910800902.6A Active CN110623958B (zh) 2016-09-05 2017-09-05 抗流感病毒嘧啶衍生物

Country Status (14)

Country Link
US (4) US11136319B2 (enExample)
EP (1) EP3502112B1 (enExample)
JP (1) JP6838773B2 (enExample)
KR (1) KR102312088B1 (enExample)
CN (3) CN110627784B (enExample)
AU (1) AU2017320088B2 (enExample)
CA (1) CA3035680C (enExample)
DK (1) DK3502112T3 (enExample)
IL (1) IL265166B (enExample)
MX (1) MX394277B (enExample)
RU (1) RU2727772C1 (enExample)
SG (1) SG11201901894TA (enExample)
WO (1) WO2018041263A1 (enExample)
ZA (1) ZA201901886B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107759571B (zh) 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
MX394277B (es) * 2016-09-05 2025-03-24 Guangdong Raynovent Biotech Co Ltd Derivados de pirimidina contra virus de la influenza
CA3045371C (en) 2016-12-15 2024-05-14 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
WO2018127096A1 (en) * 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
NZ767352A (en) * 2018-03-05 2023-05-26 Guangdong Raynovent Biotech Co Ltd Crystal form and salt form of pyridopyrazole compound and preparation method therefor
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
CN114127068B (zh) * 2019-07-22 2024-05-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
CN111454166B (zh) * 2019-12-30 2021-02-26 广东莱佛士制药技术有限公司 制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
WO2022089261A1 (zh) * 2020-10-29 2022-05-05 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法
CN114569562B (zh) * 2020-12-01 2025-07-29 南通诺泰生物医药技术有限公司 一种抗流感病毒的药物组合物
CN117700412A (zh) * 2023-11-20 2024-03-15 广东众生睿创生物科技有限公司 一种昂拉地韦工艺杂质及其制备和检测方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458408A (zh) * 2009-06-17 2012-05-16 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
CN103492381A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2016020526A1 (en) * 2014-08-08 2016-02-11 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
CN106854205A (zh) * 2015-12-09 2017-06-16 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102600A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017133670A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
CN107759571B (zh) * 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
MX394277B (es) * 2016-09-05 2025-03-24 Guangdong Raynovent Biotech Co Ltd Derivados de pirimidina contra virus de la influenza
NZ767352A (en) * 2018-03-05 2023-05-26 Guangdong Raynovent Biotech Co Ltd Crystal form and salt form of pyridopyrazole compound and preparation method therefor
CN114127068B (zh) * 2019-07-22 2024-05-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458408A (zh) * 2009-06-17 2012-05-16 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
CN103492381A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2016020526A1 (en) * 2014-08-08 2016-02-11 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
CN106854205A (zh) * 2015-12-09 2017-06-16 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途

Also Published As

Publication number Publication date
BR112019004420A2 (pt) 2019-05-28
US20250250275A1 (en) 2025-08-07
CN110623958B (zh) 2022-05-17
EP3502112B1 (en) 2025-07-02
MX2019002541A (es) 2019-07-01
US20210032238A1 (en) 2021-02-04
CN109790159B (zh) 2020-01-14
WO2018041263A1 (zh) 2018-03-08
CN110627784A (zh) 2019-12-31
NZ751964A (en) 2021-02-26
JP6838773B2 (ja) 2021-03-03
EP3502112A4 (en) 2019-06-26
KR102312088B1 (ko) 2021-10-14
CN110623958A (zh) 2019-12-31
KR20190056380A (ko) 2019-05-24
US20230339943A1 (en) 2023-10-26
EP3502112A1 (en) 2019-06-26
CA3035680C (en) 2023-05-02
US20220135558A1 (en) 2022-05-05
AU2017320088A1 (en) 2019-04-18
CN109790159A (zh) 2019-05-21
IL265166A (en) 2019-05-30
MX394277B (es) 2025-03-24
AU2017320088B2 (en) 2020-01-30
RU2727772C1 (ru) 2020-07-23
DK3502112T3 (da) 2025-09-22
US11136319B2 (en) 2021-10-05
US11725009B2 (en) 2023-08-15
SG11201901894TA (en) 2019-04-29
IL265166B (en) 2021-09-30
CA3035680A1 (en) 2018-03-08
ZA201901886B (en) 2021-01-27
JP2019529386A (ja) 2019-10-17
US12319692B2 (en) 2025-06-03

Similar Documents

Publication Publication Date Title
CN110623958B (zh) 抗流感病毒嘧啶衍生物
JP2019529386A5 (enExample)
CN110944989B (zh) 作为egfr激酶抑制剂的芳基磷氧化合物
CN107531711B (zh) Janus激酶抑制剂
CN107922349B (zh) 作为fgfr和vegfr抑制剂的乙烯基化合物
CN110225781B (zh) 噻唑衍生物及其应用
WO2018192493A1 (zh) 作为pcsk9抑制剂的哌啶类化合物
WO2018233648A1 (zh) 作为TLR8激动剂的异噻唑并[4,3-d]嘧啶-5,7-二胺衍生物
CN110461855B (zh) 氮杂环丁烷衍生物
WO2018036470A1 (zh) 作为pde4抑制剂的并环类化合物
CN109803951B (zh) 作为cccDNA抑制剂的磺酰胺类化合物
EP3498715B1 (en) Anti-hcmv virus compound
HK40003826B (en) Anti-influenza virus pyrimidine derivatives
HK40003826A (en) Anti-influenza virus pyrimidine derivatives
BR112019004420B1 (pt) Composição farmacêutica
HK40009263B (en) Azetidine derivative
HK40009263A (en) Azetidine derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 510700 Room 501, building D, 288 Shenzhou Road, Huangpu District, Guangzhou City, Guangdong Province

Applicant after: Guangdong Raynovent Biotech Co.,Ltd.

Address before: 3406a, jinzhonghuan international business building, 3037 Jintian Road, Fu'an community, Futian street, Futian District, Shenzhen, Guangdong 518000

Applicant before: Guangdong Raynovent Biotech Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant